Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Income from Non-Controlling Interests (2022 - 2023)

Historic Income from Non-Controlling Interests for Pharmaceuticals (CASI) over the last 2 years, with Q4 2023 value amounting to -$742000.0.

  • Pharmaceuticals' Income from Non-Controlling Interests rose 8945.57% to -$742000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$2.6 million, marking a year-over-year increase of 7022.88%. This contributed to the annual value of -$2.6 million for FY2023, which is 7022.88% up from last year.
  • As of Q4 2023, Pharmaceuticals' Income from Non-Controlling Interests stood at -$742000.0, which was up 8945.57% from -$600000.0 recorded in Q3 2023.
  • In the past 5 years, Pharmaceuticals' Income from Non-Controlling Interests ranged from a high of -$417000.0 in Q1 2022 and a low of -$7.0 million during Q4 2022